206 related articles for article (PubMed ID: 21422499)
21. Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.
Ogawa S; Sanada M; Shih LY; Suzuki T; Otsu M; Nakauchi H; Koeffler HP
Cell Cycle; 2010 Mar; 9(6):1051-6. PubMed ID: 20237427
[TBL] [Abstract][Full Text] [Related]
22. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
23. Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies.
Adélaïde J; Gelsi-Boyer V; Rocquain J; Carbuccia N; Birnbaum DJ; Finetti P; Bertucci F; Mozziconacci MJ; Vey N; Birnbaum D; Chaffanet M
Leukemia; 2010 Aug; 24(8):1539-41. PubMed ID: 20555362
[No Abstract] [Full Text] [Related]
24. Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
Sargin B; Choudhary C; Crosetto N; Schmidt MHH; Grundler R; Rensinghoff M; Thiessen C; Tickenbrock L; Schwäble J; Brandts C; August B; Koschmieder S; Bandi SR; Duyster J; Berdel WE; Müller-Tidow C; Dikic I; Serve H
Blood; 2007 Aug; 110(3):1004-12. PubMed ID: 17446348
[TBL] [Abstract][Full Text] [Related]
25. High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions.
Kumar EA; Charvet CD; Lokesh GL; Natarajan A
Anal Biochem; 2011 Apr; 411(2):254-60. PubMed ID: 21129358
[TBL] [Abstract][Full Text] [Related]
26. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
Fernandes MS; Reddy MM; Croteau NJ; Walz C; Weisbach H; Podar K; Band H; Carroll M; Reiter A; Larson RA; Salgia R; Griffin JD; Sattler M
J Biol Chem; 2010 Oct; 285(42):32596-605. PubMed ID: 20622007
[TBL] [Abstract][Full Text] [Related]
27. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
28. Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms.
Ogawa S; Shih LY; Suzuki T; Otsu M; Nakauchi H; Koeffler HP; Sanada M
Clin Cancer Res; 2010 Aug; 16(15):3825-31. PubMed ID: 20547695
[TBL] [Abstract][Full Text] [Related]
29. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
[TBL] [Abstract][Full Text] [Related]
30. The Cbl RING finger C-terminal flank controls epidermal growth factor receptor fate downstream of receptor ubiquitination.
Visser GD; Lill NL
Exp Cell Res; 2005 Dec; 311(2):281-93. PubMed ID: 16246327
[TBL] [Abstract][Full Text] [Related]
31. The Cbl family of signal transduction molecules.
Smit L; Borst J
Crit Rev Oncog; 1997; 8(4):359-79. PubMed ID: 9622055
[TBL] [Abstract][Full Text] [Related]
32. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor.
Zuo W; Huang F; Chiang YJ; Li M; Du J; Ding Y; Zhang T; Lee HW; Jeong LS; Chen Y; Deng H; Feng XH; Luo S; Gao C; Chen YG
Mol Cell; 2013 Feb; 49(3):499-510. PubMed ID: 23290524
[TBL] [Abstract][Full Text] [Related]
33. Casitas B-cell lymphoma (Cbl) proteins protect mammary epithelial cells from proteotoxicity of active c-Src accumulation.
Mukhopadhyay C; Triplett A; Bargar T; Heckman C; Wagner KU; Naramura M
Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8228-E8237. PubMed ID: 27930322
[TBL] [Abstract][Full Text] [Related]
34. Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.
Duan L; Raja SM; Chen G; Virmani S; Williams SH; Clubb RJ; Mukhopadhyay C; Rainey MA; Ying G; Dimri M; Chen J; Reddi AL; Naramura M; Band V; Band H
J Biol Chem; 2011 Jan; 286(1):620-33. PubMed ID: 20940296
[TBL] [Abstract][Full Text] [Related]
35. Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.
Wisniewski DJ; Liyasova MS; Korrapati S; Zhang X; Ratnayake S; Chen Q; Gilbert SF; Catalano A; Voeller D; Meerzaman D; Guha U; Porat-Shliom N; Annunziata CM; Lipkowitz S
J Biol Chem; 2023 Jan; 299(1):102766. PubMed ID: 36470425
[TBL] [Abstract][Full Text] [Related]
36. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
[TBL] [Abstract][Full Text] [Related]
37. The Cbl protooncogene product: from an enigmatic oncogene to center stage of signal transduction.
Miyake S; Lupher ML; Andoniou CE; Lill NL; Ota S; Douillard P; Rao N; Band H
Crit Rev Oncog; 1997; 8(2-3):189-218. PubMed ID: 9570294
[TBL] [Abstract][Full Text] [Related]
38. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.
Peschard P; Ishiyama N; Lin T; Lipkowitz S; Park M
J Biol Chem; 2004 Jul; 279(28):29565-71. PubMed ID: 15123609
[TBL] [Abstract][Full Text] [Related]
39. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
40. Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.
Liyasova MS; Ma K; Lipkowitz S
Clin Cancer Res; 2015 Apr; 21(8):1789-94. PubMed ID: 25477533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
